After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

In trials of Wegovy, up to 40% of weight loss was from a decrease in lean or fat-free mass, rather than excess fat. In addition, quitting the drugs can mean adding back the pounds.

As of May 22, manufacturers are no longer allowed to distribute the compounded versions of semaglutide, which Novo Nordisk sells under the brand Wegovy for weight loss and Ozempic for diabetes.

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial, according to the findings published Wednesday in the New England ...

Contrave and Wegovy are FDA approved for: weight loss and management, in adults with a body mass index (BMI) of 30 kilograms per square meter (kg/m 2 ) or greater, which indicates obesity ...

Cigna now offers employers $200 Wegovy, Zepbound copay option. The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.